Trastuzumab Deruxtecan (Solution) provides a HER2-targeting antibody-drug conjugate (ADC) for cancer and oncology research and specifically combines trastuzumab with a deruxtecan (DXd) topoisomerase I inhibitor payload, supporting studies of HER2-targeted cytotoxicity and ADC mechanisms.
Key Features and Benefits
- HER2-Targeting ADC: Combines the HER2-directed monoclonal antibody trastuzumab with a cytotoxic DXd payload.
- DXd Payload: Contains a potent topoisomerase I inhibitor specifically designed for intracellular delivery through the ADC platform.
- HER2 Recognition: Supports studies of HER2 expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Cleavable Linker: Uses a protease-cleavable linker designed to specifically facilitate intracellular release of the DXd payload.
- High Drug-to-Antibody Ratio: Features a relatively high DAR, supporting efficient payload delivery in HER2-targeted ADC research.
- Targeted Payload Delivery: Supports investigation of antibody-mediated DXd delivery to HER2-expressing cancer cells.
- Topoisomerase I Inhibition: DXd disrupts DNA replication, specifically supporting studies of ADC-mediated cytotoxic responses.
- Solution Format: Provides Trastuzumab Deruxtecan in solution form specifically for convenient experimental use and assay preparation.
Applications
- HER2-Positive Cancer Research: Supports studies involving tumor models with elevated HER2 expression.
- HER2-Low Cancer Research: Useful for investigating ADC activity in cancer models with lower levels of HER2 expression.
- Breast Cancer Research: Supports studies of HER2-targeted ADC mechanisms in relevant breast cancer models.
- Gastric Cancer Research: Especially useful for investigating HER2-directed approaches in gastric and gastroesophageal cancer models.
- Lung Cancer Research: Supports studies involving HER2-expressing or HER2-altered lung cancer models.
- ADC Research: Useful for studying antibody targeting, internalization, payload release, and cytotoxic activity.
- Mechanism-of-Action Studies: Supports investigation of HER2 targeting and DXd-mediated topoisomerase I inhibition.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve protein and conjugate stability.
Trastuzumab Deruxtecan (Solution) combines HER2-directed antibody targeting with a DXd topoisomerase I inhibitor payload and specifically supports HER2-positive and HER2-low cancer, ADC, targeted drug delivery, and oncology research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
